

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

April 13, 2018

To,
The Manager,
Listing Department,
BSE Limited,
Bombay Stock Exchange,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Subject: Statement of Investor Complaints for the quarter ended 31st March, 2018.
Ref: Scrip code 956084 and ISIN INE988W07019


Dear Sir/Madam,

With reference to the subject matter, please find below the statement on the investor complaints for Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited) as required under Regulation 13(3) of Chapter III of SEBI (Listing Obligations and Disclosure Requirements), 2015 for the quarter ended 31st March, 2018.

| Particulars | Status of complaints |
|--|----------------------|
| Investor complaints pending at the beginning of the quarter | Nil |
| Investor complaints received during the quarter | Nil |
| Investor complaints disposed of during the quarter | Not applicable |
| Investor complaints remaining unresolved at the end of the quarter | Nil |

We kindly request you to take the above information on your records.
Thanking you.

For Genlink Pharma Solutions Private Limited



Anand Pratulchandra Shah
Director & Compliance Officer
DIN: 00597145

